FibroGen announces interim results of Phase 2 clinical trial sparing DMD patients with the drug pamerevlumab

recently, FibroGen(http://announced the interim results of thepamerevlumab, adrug(http:// for the treatment of Duchenne muscular dystrophy (DMD), in theof the Phase 2 clinicaltrial(http:// in the treatment of non-bed-in-bed DMD patientsPamrevlumab is a monoclonal antibody that targets connective tissue growth factor (CTGF)The results of the mid-term trial showed that pamrevlumab was able to alleviate the decline in lung and heart function compared to the patient's historical dataAbout pamrevlumabthe development of FibroGen is a CTGF whole-humanized monoclonal antibodyCTGF is a common factor in fibrosis and hyperplasia disorders, characterized by persistent and excessive scar tissue production leading to organ dysfunction and failurecurrently, pamrevlumab is currently used in clinical trials to treat patients with non-bedd DMD, isopathic pulmonary fibrosis (IPF), and localized advanced pancreatic cancerIn these clinical trials, it has shown consistent safety and tolerabilitystudy 07a total of 21 DMD patients received pamrevlumab treatment in an open label called Study 079, a single arm Phase 2 clinical trialresults showed that after 52 weeks of treatment, the patient's heart function index improved compared to the baselineUsing heart magnetic resonance imaging, the researcherstest(http://the patient's percentage of the percentage of the patient's left ventricular blood rate (LVEF) and myocardial fibrosisIn the group of intended patients (ITT), the average LVEF% of patients increased by 0.29% compared to the baselinethe treatment of pamrevlumab led to an average increase of 1.79 percent in patients with baseline LVEF% greater than 50%Historical studies of natural diseases have shown that patients typically have a 0.82% decrease in LVEF in a yearIn addition to improving this heart function index, pamrevlumab also reduces the level of fibrosis of the heart muscle accordinglyAt the same time, the rate of decline in lung function and the rate of decline in upper arm muscle function were also mitigatedthe Phase 2 clinical trial is still in progress and patients are expected to receive treatment for up to 156 weeks